Yildiz Gazi, Yavuzcan Ali, Yildiz Pinar, Süer Necdet, Tandoğan Nilgün
Department of Obstetrics and Gynecology, Bucak State Hospital, Burdur, Turkey.
Ginekol Pol. 2012 Aug;83(8):598-603.
To determine the prevalence and the role of hereditary thrombophilia caused by Factor V Leiden (G1691A), prothrombin G20210A or methylenetetrahydrofolate reductase (MTHFR) C677T gene mutations in recurrent pregnancy loss.
One hundred and nine patients, who were admitted to the 3rd Obstetrics and Gynecology Outpatient Clinic in Goztepe Training and Research Hospital between 2006 and 2008, were included into the study The study group consisted of fifty-seven patients with a history of 3 miscarriages before 20 weeks of gestation and the control group consisted of forty-seven patients with at least one live birth without any history of miscarriage or pregnancy complications. The maternal blood was evaluated for Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations.
No statistically significant difference was found between the study and the control groups in terms of the prevalence of Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations (p=0.534/ p=0.452/p=0.656, respectively and p<0.05). Furthermore, the prevalence of multiple gene mutations was not statistically different between the groups (p=0.375 and p<0.05) either.
Routine screening for Factor V Leiden (G1691A), prothrombin G20210A and MTHFR C677T gene mutations in patients with a history of recurrent pregnancy loss is not recommended in Turkish women.
确定由凝血因子V莱顿突变(G1691A)、凝血酶原G20210A或亚甲基四氢叶酸还原酶(MTHFR)C677T基因突变引起的遗传性血栓形成倾向在复发性流产中的患病率及其作用。
纳入2006年至2008年间在戈兹特佩培训和研究医院第三妇产科门诊就诊的109例患者。研究组由57例妊娠20周前有3次流产史的患者组成,对照组由47例至少有一次活产且无流产或妊娠并发症史的患者组成。对孕妇血液进行凝血因子V莱顿突变(G1691A)、凝血酶原G20210A和MTHFR C677T基因突变检测。
研究组与对照组在凝血因子V莱顿突变(G1691A)、凝血酶原G20210A和MTHFR C677T基因突变患病率方面无统计学显著差异(分别为p = 0.534 / p = 0.452 / p = 0.656,且p < 0.05)。此外,两组之间多重基因突变的患病率也无统计学差异(p = 0.375,且p < 0.05)。
不建议对有复发性流产史的土耳其女性常规筛查凝血因子V莱顿突变(G1691A)、凝血酶原G20210A和MTHFR C677T基因突变。